Lei Yu

List of Publications by Year
in descending order

52 papers	1,196 citations	471509 17 h-index	434195 31 g-index
55 all docs	55 docs citations	55 times ranked	1975 citing authors

#	Article	IF	Citations
1	Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma. Blood Advances, 2022, 6, 293-296.	5.2	4
2	The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients. Scientific Reports, 2022, 12, 378.	3.3	18
3	Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells. Biochemical and Biophysical Research Communications, 2022, 595, 54-61.	2.1	9
4	Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis. Journal of Controlled Release, 2022, 343, 175-186.	9.9	37
5	Antiâ€CD19 and antiâ€BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stemâ€cell transplantation for highâ€risk newly diagnosed multiple myeloma. American Journal of Hematology, 2022, 97, 537-547.	4.1	23
6	Nanoengineered Neutrophils as a Cellular Sonosensitizer for Visual Sonodynamic Therapy of Malignant Tumors. Advanced Materials, 2022, 34, e2109969.	21.0	32
7	Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. Molecular Therapy - Oncolytics, 2022, 24, 719-728.	4.4	12
8	Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells. Journal of Hematology and Oncology, 2022, 15, 39.	17.0	8
9	CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2261-2274.	2.5	8
10	Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment.. American Journal of Cancer Research, 2022, 12, 615-621.	1.4	0
11	Feasibility study of 68Ga-labeled CARÂT cells for in vivo tracking using micro-positron emission tomography imaging. Acta Pharmacologica Sinica, 2021, 42, 824-831.	6.1	18
12	Cytotoxic effect of CLLâ€'1 CARâ€'T cell immunotherapy with PDâ€'1 silencing on relapsed/refractory acute myeloid leukemia. Molecular Medicine Reports, 2021, 23, .	2.4	20
13	Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations. Bone Marrow Transplantation, 2021, 56, 1710-1713.	2.4	7
14	Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement. Frontiers in Immunology, 2021, 12, 552429.	4.8	10
15	Emerging role of RNA interference in immune cells engineering and its therapeutic synergism in immunotherapy. British Journal of Pharmacology, 2021, 178, 1741-1755.	5.4	12
16	A Photopolymerized Semi-Interpenetrating Polymer Networks-Based Hydrogel Incorporated with Nanoparticle for Local Chemotherapy of Tumors. Pharmaceutical Research, 2021, 38, 669-680.	3.5	5
17	ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft. Biomedicine and Pharmacotherapy, 2021, 137, 111339.	5.6	19
18	CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Journal of Hematology and Oncology, 2021, 14, 82.	17.0	63

#	Article	IF	Citations
19	Quantitative radio-thin-layer chromatography and positron emission tomography studies for measuring streptavidin transduced chimeric antigen receptor T cells. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1182, 122944.	2.3	4
20	Preclinical efficacy and safety evaluation of interleukin-6-knockdown CAR-T cells targeting at CD19. Annals of Translational Medicine, 2021, 9, 1713-1713.	1.7	5
21	Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden. Journal of Immunotherapy, 2020, 43, 32-37.	2.4	56
22	Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia. Translational Oncology, 2020, 13, 100838.	3.7	15
23	CARâ€T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph⁺ mixed phenotype acute leukaemia with minimal residual disease. British Journal of Haematology, 2020, 191, e47-e49.	2.5	4
24	Liver-Targeted siRNA Lipid Nanoparticles Treat Hepatic Cirrhosis by Dual Antifibrotic and Anti-inflammatory Activities. ACS Nano, 2020, 14, 6305-6322.	14.6	45
25	Gene Therapy for Hepatocellular Carcinoma Using Adenoviral Vectors Delivering a Gene Encoding IL-17A-Neutralizing Antibody Fragments. Human Gene Therapy, 2020, 31, 1074-1085.	2.7	6
26	Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma. Biomarker Research, 2020, 8, 14.	6.8	21
27	Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes. Experimental Hematology and Oncology, 2020, 9, 11.	5.0	43
28	Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma. Molecular Therapy - Oncolytics, 2020, 16, 262-271.	4.4	12
29	Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature . OncoTargets and Therapy, 2020, Volume 13, 2311-2317.	2.0	11
30	Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients. Cell Death and Disease, 2020, 11, 207.	6.3	19
31	CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 34-34.	1.4	4
32	Donor origin CAR19 T cell infusion for Bâ€ALL relapsed after allogeneic hematopoietic stem cell transplantation. Hematological Oncology, 2019, 37, 655-658.	1.7	9
33	Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells. Bone Marrow Transplantation, 2019, 54, 1138-1140.	2.4	6
34	Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkinâ€™s lymphoma. JCI Insight, 2019, 4, .	5.0	14
35	Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM. Blood, 2019, 134, 1949-1949.	1.4	8
36	Cellular Kinetics of CD19 Chimeric Antigen Receptor T Cells in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma. Blood, 2019, 134, 4097-4097.	1.4	0

#	Article	IF	Citations
37	Cholesterol Esterification Enzyme Inhibition Enhances Antitumor Effects of Human Chimeric Antigen Receptors Modified T Cells. Journal of Immunotherapy, 2018, 41, 45-52.	2.4	23
38	pPB Peptide-Mediated siRNA-Loaded Stable Nucleic Acid Lipid Nanoparticles on Targeting Therapy of Hepatic Fibrosis. Molecular Pharmaceutics, 2018, 15, 53-62.	4.6	37
39	Nanocrystal Technology as a Strategy to Improve Drug Bioavailability and Antitumor Efficacy for the Cancer Treatment. Current Pharmaceutical Design, 2018, 24, 2416-2424.	1.9	21
40	Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T₁-T₂ Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics. Theranostics, 2018, 8, 92-108.	10.0	69
41	Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study. Blood, 2018, 132, 1009-1009.	1.4	47
42	FVIIa prevents the progressive hemorrhaging of a brain contusion by protecting microvessels via formation of the TFâ€“FVIIaâ€“FXa complex. Neuroscience, 2017, 348, 114-125.	2.3	11
43	A Novel Gd-DTPA-conjugated Poly(L-Î³-glutamyl-glutamine)-paclitaxel Polymeric Delivery System for Tumor Theranostics. Scientific Reports, 2017, 7, 3799.	3.3	11
44	Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l-Î³-glutamylglutamine)â€“paclitaxel nanoconjugates. Journal of Colloid and Interface Science, 2017, 490, 783-796.	9.4	66
45	Self-Assembled Tumor-Penetrating Peptide-Modified Poly(<scp>l</scp>-Î³-glutamylglutamine)â€“Paclitaxel Nanoparticles Based on Hydrophobic Interaction for the Treatment of Glioblastoma. Bioconjugate Chemistry, 2017, 28, 2823-2831.	3.6	14
46	On-Demand Drug Release from Dual-Targeting Small Nanoparticles Triggered by High-Intensity Focused Ultrasound Enhanced Glioblastoma-Targeting Therapy. ACS Applied Materials & Interfaces, 2017, 9, 31612-31625.	8.0	75
47	Erythrocyte Membrane-Wrapped pH Sensitive Polymeric Nanoparticles for Non-Small Cell Lung Cancer Therapy. Bioconjugate Chemistry, 2017, 28, 2591-2598.	3.6	46
48	Hydrotropic polymer-based paclitaxel-loaded self-assembled nanoparticles: preparation and biological evaluation. RSC Advances, 2017, 7, 33248-33256.	3.6	8
49	Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia. Journal of Hematology and Oncology, 2017, 10, 151.	17.0	88
50	Synthesis and biological evaluation of an anticancer drug delivery system: Poly(l-Î³-glutamyl-l-carbocisteine)-paclitaxel nanoconjugate. Materials Science and Engineering C, 2017, 81, 113-119.	7.3	7
51	Poly (l-Î³-glutamylglutamine) Polymer Enhances Doxorubicin Accumulation in Multidrug Resistant Breast Cancer Cells. Molecules, 2016, 21, 720.	3.8	8
52	Investigation of the roles of exosomes in colorectal cancer liver metastasis. Oncology Reports, 2015, 33, 2445-2453.	2.6	78